Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elie Naddaf

Showing results (1-10 of 85) with videos related to

Pageof 9
Sort By:
Rheumatology (Oxford, England)|July 5, 2022
Comment on: Survival and associated comorbidities in inclusion body myositis: ReplyElie Naddaf
Frontiers in Neurology|October 14, 2022
Inclusion body myositis: Update on the diagnostic and therapeutic landscapeElie Naddaf
Continuum (Minneapolis, Minn.)|October 2, 2025
Inclusion Body MyositisElie Naddaf
European Journal of Neurology|July 17, 2025
Reply to: "Before Coming to the Conclusion That Inclusion Body Myositis Is a Risk Factor for a Heart Attack, All Influencing Factors Must Be Taken Into Account"Elie Naddaf
International Journal of Cancer|March 20, 2021
Comments on: Chemotherapy-based approach is the preferred treatment for sporadic late-onset nemaline myopathy with a monoclonal proteinElie Naddaf, Taxiarchis Kourelis
Rheumatic Diseases Clinics of North America|October 29, 2025
Updates on Diagnostic Criteria of Inclusion Body MyositisElie Naddaf, Bhaskar Roy
Muscle & Nerve|February 10, 2017
Hereditary myopathies with early respiratory insufficiency in adultsElie Naddaf, Margherita Milone
Journal of Clinical Neuromuscular Disease|February 20, 2015
Two families with MYH7 distal myopathy associated with cardiomyopathy and core formationsElie Naddaf, Andrew J Waclawik
Continuum (Minneapolis, Minn.)|October 1, 2020
Peripheral Neuropathies Associated With Monoclonal GammopathiesElie Naddaf, Michelle L Mauermann
Current Opinion in Rheumatology|July 28, 2023
Exploring challenges in the management and treatment of inclusion body myositisMichael P Skolka, Elie Naddaf
Pageof 9

Showing results (1-10 of 85) with videos related to

Sort By:
Pageof 9
Rheumatology (Oxford, England)|July 5, 2022
Comment on: Survival and associated comorbidities in inclusion body myositis: ReplyElie Naddaf
Frontiers in Neurology|October 14, 2022
Inclusion body myositis: Update on the diagnostic and therapeutic landscapeElie Naddaf
Continuum (Minneapolis, Minn.)|October 2, 2025
Inclusion Body MyositisElie Naddaf
European Journal of Neurology|July 17, 2025
Reply to: "Before Coming to the Conclusion That Inclusion Body Myositis Is a Risk Factor for a Heart Attack, All Influencing Factors Must Be Taken Into Account"Elie Naddaf
International Journal of Cancer|March 20, 2021
Comments on: Chemotherapy-based approach is the preferred treatment for sporadic late-onset nemaline myopathy with a monoclonal proteinElie Naddaf, Taxiarchis Kourelis
Rheumatic Diseases Clinics of North America|October 29, 2025
Updates on Diagnostic Criteria of Inclusion Body MyositisElie Naddaf, Bhaskar Roy
Muscle & Nerve|February 10, 2017
Hereditary myopathies with early respiratory insufficiency in adultsElie Naddaf, Margherita Milone
Journal of Clinical Neuromuscular Disease|February 20, 2015
Two families with MYH7 distal myopathy associated with cardiomyopathy and core formationsElie Naddaf, Andrew J Waclawik
Continuum (Minneapolis, Minn.)|October 1, 2020
Peripheral Neuropathies Associated With Monoclonal GammopathiesElie Naddaf, Michelle L Mauermann
Current Opinion in Rheumatology|July 28, 2023
Exploring challenges in the management and treatment of inclusion body myositisMichael P Skolka, Elie Naddaf
Pageof 9